Form 20-F ☑
|
Form 40-F ☐
|
Yes ☐
|
No ☑
|
EXFO INC.
|
|
By: /s/ Germain Lamonde
Name: Germain Lamonde
Title: President and Chief Executive Officer
|
|
§
|
Sales increase 11.9% year-over-year to US$61.8 million
|
§
|
Bookings rise 12.6% year-over-year to US$65.9 million (book-to-bill ratio of 1.07)
|
§
|
Gross margin reaches 63.1% of sales
|
§
|
Adjusted EBITDA improves 19.6% year-over-year to US$6.3 million (10.2% of sales)
|
Q1 2017
|
Q4 2016
|
Q1 2016
|
||||||||||
Physical-layer sales
|
$
|
42,016
|
$
|
39,777
|
$
|
37,477
|
||||||
Protocol-layer sales
|
20,009
|
23,445
|
18,629
|
|||||||||
Foreign exchange losses on forward exchange contracts
|
(240
|
)
|
(364
|
)
|
(874
|
)
|
||||||
Total sales
|
$
|
61,785
|
$
|
62,858
|
$
|
55,232
|
||||||
Physical-layer bookings
|
$
|
44,090
|
$
|
39,826
|
$
|
38,878
|
||||||
Protocol-layer bookings
|
22,009
|
22,969
|
20,469
|
|||||||||
Foreign exchange losses on forward exchange contracts
|
(240
|
)
|
(364
|
)
|
(874
|
)
|
||||||
Total bookings
|
$
|
65,859
|
$
|
62,431
|
$
|
58,473
|
||||||
Book-to-bill ratio (bookings/sales)
|
1.07
|
0.99
|
1.06
|
|||||||||
Gross margin before depreciation and amortization*
|
$
|
38,972
|
$
|
38,713
|
$
|
35,095
|
||||||
63.1
|
%
|
61.6
|
%
|
63.5
|
%
|
|||||||
Other selected information:
|
||||||||||||
IFRS net earnings
|
$
|
3,303
|
$
|
2,252
|
$
|
1,766
|
||||||
Amortization of intangible assets
|
$
|
427
|
$
|
292
|
$
|
300
|
||||||
Stock-based compensation costs
|
$
|
258
|
$
|
302
|
$
|
376
|
||||||
Net income tax effect of the above items
|
$
|
(64
|
)
|
$
|
(31
|
)
|
$
|
(28
|
)
|
|||
Foreign exchange gain (loss)
|
$
|
512
|
$
|
(293
|
)
|
$
|
310
|
|||||
Adjusted EBITDA*
|
$
|
6,321
|
$
|
6,172
|
$
|
5,286
|
·
|
Sales and bookings. Sales and bookings increased 11.9% and 12.6% year-over-year, respectively, mainly due to strong market demand in EXFO's three major selling regions and for optical and high-speed solutions. The company also benefited from a large wireless deal in Asia-Pacific in the first quarter. From a segmented revenue standpoint, 56% of sales originated from the Americas, 23% from EMEA and 21% from Asia-Pacific, while Physical-layer sales represented 68% of total sales and Protocol-layer sales 32%. EXFO's top customer accounted for 13.8% of sales, while the top three represented 23.3%. This represents an unusually high concentration level for EXFO, but reflects greater success with Tier-1 operators.
|
·
|
Profitability. EXFO generated adjusted EBITDA of US$6.3 million, or 10.2% of sales, in the first quarter of 2017 compared to US$5.3 million, or 9.6% of sales, in the first quarter of 2016.
|
·
|
Innovation. EXFO acquired substantially all the assets of Absolute Analysis in the first quarter to combine radio frequency (RF) test software with its own optical and Ethernet technologies. EXFO also introduced three other new solutions including a power meter, variable attenuator and optical switch modules for its LTB-8 platform dedicated to the high-speed optical lab market, a segment of increased focus. Finally, EXFO supplied OpenReach, British Telecom's local network business, with an initial order of MaxTesters to support its G.fast pilot project.
|
Q1 2017
|
Q4 2016
|
Q1 2016
|
||||||||||
IFRS net earnings for the period
|
$
|
3,303
|
$
|
2,252
|
$
|
1,766
|
||||||
Add (deduct):
|
||||||||||||
Depreciation of property, plant and equipment
|
903
|
957
|
975
|
|||||||||
Amortization of intangible assets
|
427
|
292
|
300
|
|||||||||
Interest (income) expense
|
(20
|
)
|
(112
|
)
|
63
|
|||||||
Income taxes
|
1,962
|
2,188
|
2,116
|
|||||||||
Stock-based compensation costs
|
258
|
302
|
376
|
|||||||||
Foreign exchange gain
|
(512
|
)
|
(293
|
)
|
(310
|
)
|
||||||
Adjusted EBITDA for the period
|
$
|
6,321
|
$
|
6,172
|
$
|
5,286
|
||||||
Adjusted EBITDA in percentage of sales
|
10.2
|
%
|
9.8
|
%
|
9.6
|
%
|
As at
November 30,
2016
|
As at
August 31,
2016
|
|||||||
Assets
|
||||||||
Current assets
|
||||||||
Cash
|
$
|
35,061
|
$
|
43,208
|
||||
Short-term investments
|
4,281
|
4,087
|
||||||
Accounts receivable
|
||||||||
Trade
|
43,476
|
42,993
|
||||||
Other
|
3,321
|
2,474
|
||||||
Income taxes and tax credits recoverable
|
4,047
|
4,208
|
||||||
Inventories
|
33,880
|
33,004
|
||||||
Prepaid expenses
|
2,781
|
3,099
|
||||||
126,847
|
133,073
|
|||||||
Tax credits recoverable
|
33,800
|
34,594
|
||||||
Property, plant and equipment
|
35,530
|
35,978
|
||||||
Intangible assets (note 3)
|
10,855
|
3,391
|
||||||
Goodwill
|
21,418
|
21,928
|
||||||
Deferred income tax assets
|
7,901
|
8,240
|
||||||
Other assets
|
372
|
589
|
||||||
$
|
236,723
|
$
|
237,793
|
|||||
Liabilities
|
||||||||
Current liabilities
|
||||||||
Accounts payable and accrued liabilities
|
$
|
34,779
|
$
|
37,174
|
||||
Provisions
|
308
|
299
|
||||||
Income taxes payable
|
567
|
971
|
||||||
Deferred revenue
|
8,910
|
9,486
|
||||||
44,564
|
47,930
|
|||||||
Deferred revenue
|
5,681
|
5,530
|
||||||
Deferred income tax liabilities
|
2,546
|
2,857
|
||||||
Other liabilities
|
29
|
75
|
||||||
52,820
|
56,392
|
|||||||
Shareholders' equity
|
||||||||
Share capital (note 5)
|
89,352
|
85,516
|
||||||
Contributed surplus
|
18,018
|
18,150
|
||||||
Retained earnings
|
129,612
|
126,309
|
||||||
Accumulated other comprehensive loss
|
(53,079
|
)
|
(48,574
|
)
|
||||
183,903
|
181,401
|
|||||||
$
|
236,723
|
$
|
237,793
|
Three months ended
November 30,
|
||||||||
2016
|
2015
|
|||||||
Sales
|
$
|
61,785
|
$
|
55,232
|
||||
Cost of sales (1) (note 6)
|
22,813
|
20,137
|
||||||
Selling and administrative (note 6)
|
21,595
|
20,252
|
||||||
Net research and development (note 6)
|
11,314
|
9,933
|
||||||
Depreciation of property, plant and equipment (note 6)
|
903
|
975
|
||||||
Amortization of intangible assets (note 6)
|
427
|
300
|
||||||
Interest (income) expense
|
(20
|
)
|
63
|
|||||
Foreign exchange gain
|
(512
|
)
|
(310
|
)
|
||||
Earnings before income taxes
|
5,265
|
3,882
|
||||||
Income taxes (note 7)
|
1,962
|
2,116
|
||||||
Net earnings for the period
|
$
|
3,303
|
$
|
1,766
|
||||
Basic and diluted net earnings per share
|
$
|
0.06
|
$
|
0.03
|
||||
Basic weighted average number of shares outstanding (000's)
|
53,884
|
53,814
|
||||||
Diluted weighted average number of shares outstanding (000's) (note 8)
|
55,001
|
54,535
|
(1)
|
The cost of sales is exclusive of depreciation and amortization, shown separately.
|
Three months ended
November 30,
|
||||||||
2016
|
2015
|
|||||||
Net earnings for the period
|
$
|
3,303
|
$
|
1,766
|
||||
Other comprehensive income (loss), net of income taxes
|
||||||||
Items that will not be reclassified subsequently to net earnings
|
||||||||
Foreign currency translation adjustment
|
(4,217
|
)
|
(2,509
|
)
|
||||
Items that may be reclassified subsequently to net earnings
|
||||||||
Unrealized gains/losses on forward exchange contracts
|
(561
|
)
|
(270
|
)
|
||||
Reclassification of realized gains/losses on forward exchange contracts in net earnings
|
181
|
878
|
||||||
Deferred income tax effect of gains/losses on forward exchange contracts
|
92
|
(148
|
)
|
|||||
Other comprehensive loss
|
(4,505
|
)
|
(2,049
|
)
|
||||
Comprehensive loss for the period
|
$
|
(1,202
|
)
|
$
|
(283
|
)
|
Three months ended November 30, 2015
|
||||||||||||||||||||
Share
capital
|
Contributed surplus
|
Retained earnings
|
Accumulated other comprehensive loss
|
Total
shareholders' equity
|
||||||||||||||||
Balance as at September 1, 2015
|
$
|
86,045
|
$
|
17,778
|
$
|
117,409
|
$
|
(52,005
|
)
|
$
|
169,227
|
|||||||||
Redemption of share capital (note 5)
|
(1
|
)
|
–
|
–
|
–
|
(1
|
)
|
|||||||||||||
Reclassification of stock-based compensation costs (note 5)
|
723
|
(723
|
)
|
–
|
–
|
–
|
||||||||||||||
Stock-based compensation costs
|
–
|
341
|
–
|
–
|
341
|
|||||||||||||||
Net earnings for the period
|
–
|
–
|
1,766
|
–
|
1,766
|
|||||||||||||||
Other comprehensive income (loss)
|
||||||||||||||||||||
Foreign currency translation adjustment
|
–
|
–
|
–
|
(2,509
|
)
|
(2,509
|
)
|
|||||||||||||
Changes in unrealized losses on forward exchange contracts, net of deferred income taxes of $148
|
–
|
–
|
–
|
460
|
460
|
|||||||||||||||
Total comprehensive loss for the period
|
(283
|
)
|
||||||||||||||||||
Balance as at November 30, 2015
|
$
|
86,767
|
$
|
17,396
|
$
|
119,175
|
$
|
(54,054
|
)
|
$
|
169,284
|
Three months ended November 30, 2016
|
||||||||||||||||||||
Share
capital
|
Contributed surplus
|
Retained earnings
|
Accumulated other comprehensive loss
|
Total
shareholders' equity
|
||||||||||||||||
Balance as at September 1, 2016
|
$
|
85,516
|
$
|
18,150
|
$
|
126,309
|
$
|
(48,574
|
)
|
$
|
181,401
|
|||||||||
Issuance of share capital (notes 3 and 5)
|
3,490
|
–
|
–
|
–
|
3,490
|
|||||||||||||||
Reclassification of stock-based compensation costs (note 5)
|
346
|
(346
|
)
|
–
|
–
|
–
|
||||||||||||||
Stock-based compensation costs
|
–
|
214
|
–
|
–
|
214
|
|||||||||||||||
Net earnings for the period
|
–
|
–
|
3,303
|
–
|
3,303
|
|||||||||||||||
Other comprehensive loss
|
||||||||||||||||||||
Foreign currency translation adjustment
|
–
|
–
|
–
|
(4,217
|
)
|
(4,217
|
)
|
|||||||||||||
Changes in unrealized gains/losses on forward exchange contracts, net of deferred income taxes of $92
|
–
|
–
|
–
|
(288
|
)
|
(288
|
)
|
|||||||||||||
Total comprehensive loss for the period
|
(1,202
|
)
|
||||||||||||||||||
Balance as at November 30, 2016
|
$
|
89,352
|
$
|
18,018
|
$
|
129,612
|
$
|
(53,079
|
)
|
$
|
183,903
|
Three months ended
November 30,
|
||||||||
2016
|
2015
|
|||||||
Cash flows from operating activities
|
||||||||
Net earnings for the period
|
$
|
3,303
|
$
|
1,766
|
||||
Add (deduct) items not affecting cash
|
||||||||
Stock-based compensation costs
|
258
|
376
|
||||||
Depreciation and amortization
|
1,330
|
1,275
|
||||||
Deferred revenue
|
(75
|
)
|
1,511
|
|||||
Deferred income taxes
|
147
|
573
|
||||||
Changes in foreign exchange gain/loss
|
(538
|
)
|
(344
|
)
|
||||
4,425
|
5,157
|
|||||||
Changes in non-cash operating items
|
||||||||
Accounts receivable
|
(2,558
|
)
|
(2,024
|
)
|
||||
Income taxes and tax credits
|
(344
|
)
|
(278
|
)
|
||||
Inventories
|
(1,248
|
)
|
(3,226
|
)
|
||||
Prepaid expenses
|
258
|
54
|
||||||
Other assets
|
13
|
193
|
||||||
Accounts payable, accrued liabilities and provisions
|
(1,425
|
)
|
3,375
|
|||||
Other liabilities
|
–
|
(28
|
)
|
|||||
(879
|
)
|
3,223
|
||||||
Cash flows from investing activities
|
||||||||
Additions to short-term investments
|
(296
|
)
|
(21
|
)
|
||||
Additions to capital assets
|
(1,237
|
)
|
(1,309
|
)
|
||||
Business combination (note 3)
|
(5,000
|
)
|
–
|
|||||
(6,533
|
)
|
(1,330
|
)
|
|||||
Cash flows from financing activities
|
||||||||
Bank loan
|
–
|
315
|
||||||
Redemption of share capital
|
–
|
(1
|
)
|
|||||
–
|
314
|
|||||||
Effect of foreign exchange rate changes on cash
|
(735
|
)
|
(197
|
)
|
||||
Change in cash
|
(8,147
|
)
|
2,010
|
|||||
Cash – Beginning of the period
|
43,208
|
25,864
|
||||||
Cash – End of the period
|
$
|
35,061
|
$
|
27,874
|
||||
Supplementary information
|
||||||||
Income taxes paid
|
$
|
958
|
$
|
608
|
1
|
Nature of Activities and Incorporation
|
2
|
Basis of Presentation
|
3
|
Business Combination
|
Assets acquired
|
||||
Core technology
|
$
|
8,254
|
||
Other assets
|
236
|
|||
Net identifiable assets acquired and fair value of the total consideration transferred
|
$
|
8,490
|
4
|
Financial Instruments
|
Level 1: |
Quoted prices (unadjusted) in active market for identical assets or liabilities
|
Level 2: |
Inputs other than quoted prices included within Level 1 that are observable for the asset and liability, either directly or indirectly
|
Level 3: |
Unobservable inputs for the asset or liability
|
As at November 30, 2016
|
As at August 31, 2016
|
|||||||||||||||
Level 1
|
Level 2
|
Level 1
|
Level 2
|
|||||||||||||
Financial assets
|
||||||||||||||||
Short-term investments
|
$
|
4,281
|
$
|
–
|
$
|
4,087
|
$
|
–
|
||||||||
Forward exchange contracts
|
$
|
–
|
$
|
461
|
$
|
–
|
$
|
980
|
||||||||
Financial Liabilities
|
||||||||||||||||
Forward exchange contracts
|
$
|
–
|
$
|
903
|
$
|
–
|
$
|
1,120
|
Expiry dates
|
Contractual
amounts
|
Weighted average
contractual forward rates
|
|||||||
December 2016 to August 2017
|
$
|
17,900
|
1.2995
|
||||||
September 2017 to August 2018
|
12,700
|
1.3376
|
|||||||
September 2018 to December 2018
|
2,500
|
1.3585
|
|||||||
Total
|
$
|
33,100
|
1.3185
|
Expiry dates
|
Contractual
amounts
|
Weighted average
contractual forward rates
|
|||||||
December 2016 to August 2017
|
$
|
3,000
|
71.06
|
||||||
September 2017 to January 2018
|
2,000
|
70.76
|
|||||||
Total
|
$
|
5,000
|
70.94
|
5
|
Share Capital
|
Three months ended November 30, 2015
|
||||||||||||||||||||
Multiple voting shares
|
Subordinate voting shares
|
|||||||||||||||||||
Number
|
Amount
|
Number
|
Amount
|
Total
amount
|
||||||||||||||||
Balance as at September 1, 2015
|
31,643,000
|
$
|
1
|
22,092,034
|
$
|
86,044
|
$
|
86,045
|
||||||||||||
Redemption of restricted share units
|
−
|
−
|
155,784
|
−
|
−
|
|||||||||||||||
Redemption of deferred share units
|
−
|
−
|
653
|
−
|
−
|
|||||||||||||||
Redemption of share capital
|
−
|
−
|
(200
|
)
|
(1
|
)
|
(1
|
)
|
||||||||||||
Reclassification of stock-based compensation costs to share capital upon exercise of stock awards
|
−
|
−
|
−
|
723
|
723
|
|||||||||||||||
Balance as at November 30, 2015
|
31,643,000
|
$
|
1
|
22,248,271
|
$
|
86,766
|
$
|
86,767
|
Three months ended November 30, 2016
|
||||||||||||||||||||
Multiple voting shares
|
Subordinate voting shares
|
|||||||||||||||||||
Number
|
Amount
|
Number
|
Amount
|
Total
amount
|
||||||||||||||||
Balance as at September 1, 2016
|
31,643,000
|
$
|
1
|
21,917,942
|
$
|
85,515
|
$
|
85,516
|
||||||||||||
Issuance of share capital (note 3)
|
−
|
−
|
793,070
|
3,490
|
3,490
|
|||||||||||||||
Redemption of restricted share units
|
−
|
−
|
88,371
|
−
|
−
|
|||||||||||||||
Reclassification of stock-based compensation costs to share capital upon exercise of stock awards
|
−
|
−
|
−
|
346
|
346
|
|||||||||||||||
Balance as at November 30, 2016
|
31,643,000
|
$
|
1
|
22,799,383
|
$
|
89,351
|
$
|
89,352
|
6
|
Statements of Earnings
|
Three months ended
November 30,
|
||||||||
2016
|
2015
|
|||||||
Gross research and development expenses
|
$
|
12,640
|
$
|
11,279
|
||||
Research and development tax credits and grants
|
(1,326
|
)
|
(1,346
|
)
|
||||
Net research and development expenses for the period
|
$
|
11,314
|
$
|
9,933
|
Three months ended
November 30,
|
||||||||
2016
|
2015
|
|||||||
Inventory write-down for the period
|
$
|
1,129
|
$
|
847
|
Three months ended
November 30,
|
||||||||
2016
|
2015
|
|||||||
Cost of sales
|
||||||||
Depreciation of property, plant and equipment
|
$
|
359
|
$
|
323
|
||||
Amortization of intangible assets
|
296
|
177
|
||||||
655
|
500
|
|||||||
Selling and administrative expenses
|
||||||||
Depreciation of property, plant and equipment
|
118
|
146
|
||||||
Amortization of intangible assets
|
19
|
18
|
||||||
137
|
164
|
|||||||
Net research and development expenses
|
||||||||
Depreciation of property, plant and equipment
|
426
|
506
|
||||||
Amortization of intangible assets
|
112
|
105
|
||||||
538
|
611
|
|||||||
$
|
1,330
|
$
|
1,275
|
|||||
Depreciation of property, plant and equipment
|
$
|
903
|
$
|
975
|
||||
Amortization of intangible assets
|
427
|
300
|
||||||
$
|
1,330
|
$
|
1,275
|
Three months ended
November 30,
|
||||||||
2016
|
2015
|
|||||||
Salaries and benefits
|
$
|
28,778
|
$
|
26,964
|
||||
Stock-based compensation costs
|
258
|
376
|
||||||
Total employee compensation for the period
|
$
|
29,036
|
$
|
27,340
|
Three months ended
November 30,
|
||||||||
2016
|
2015
|
|||||||
Cost of sales
|
$
|
27
|
$
|
31
|
||||
Selling and administrative expenses
|
179
|
266
|
||||||
Net research and development expenses
|
52
|
79
|
||||||
Total stock-based compensation for the period
|
$
|
258
|
$
|
376
|
7
|
Income Taxes
|
Three months ended
November 30,
|
||||||||
2016
|
2015
|
|||||||
Income tax provision at combined Canadian federal and provincial statutory tax rate (27%)
|
$
|
1,422
|
$
|
1,048
|
||||
Increase (decrease) due to:
|
||||||||
Foreign income taxed at different rates
|
(172
|
)
|
(158
|
)
|
||||
Non-deductible loss
|
194
|
204
|
||||||
Non-deductible expenses
|
173
|
170
|
||||||
Change in tax rates
|
(89
|
)
|
−
|
|||||
Foreign exchange effect of translation of foreign subsidiaries
|
(122
|
)
|
(150
|
)
|
||||
Utilization of previously unrecognized deferred income tax assets
|
(156
|
)
|
−
|
|||||
Unrecognized deferred income tax assets on temporary deductible differences and unused tax losses
|
850
|
1,012
|
||||||
Other
|
(138
|
)
|
(10
|
)
|
||||
Income tax provision for the period
|
$
|
1,962
|
$
|
2,116
|
Three months ended
November 30,
|
||||||||
2016
|
2015
|
|||||||
Current
|
$
|
1,815
|
$
|
1,543
|
||||
Deferred
|
147
|
573
|
||||||
$
|
1,962
|
$
|
2,116
|
8
|
Earnings per Share
|
Three months ended
November 30,
|
||||||||
2016
|
2015
|
|||||||
Basic weighted average number of shares outstanding (000's)
|
53,884
|
53,814
|
||||||
Plus dilutive effect of (000's):
|
||||||||
Restricted share units
|
958
|
607
|
||||||
Deferred share units
|
159
|
114
|
||||||
Diluted weighted average number of shares outstanding (000's)
|
55,001
|
54,535
|
||||||
Stock awards excluded from the calculation of diluted weighted average number of shares because their exercise price was greater than the average market price of the common shares (000's)
|
−
|
57
|
Three months ended
November 30,
|
Three months ended
November 30,
|
|||||||||||||||
2016
|
2015
|
2016
|
2015
|
|||||||||||||
Sales
|
$
|
61,785
|
$
|
55,232
|
100.0
|
%
|
100.0
|
%
|
||||||||
Cost of sales (1)
|
22,813
|
20,137
|
36.9
|
36.5
|
||||||||||||
Selling and administrative
|
21,595
|
20,252
|
35.0
|
36.7
|
||||||||||||
Net research and development
|
11,314
|
9,933
|
18.3
|
18.0
|
||||||||||||
Depreciation of property, plant and equipment
|
903
|
975
|
1.4
|
1.7
|
||||||||||||
Amortization of intangible assets
|
427
|
300
|
0.7
|
0.5
|
||||||||||||
Interest (income) expense
|
(20
|
)
|
63
|
-
|
0.1
|
|||||||||||
Foreign exchange gain
|
(512
|
)
|
(310
|
)
|
(0.8
|
)
|
(0.5
|
)
|
||||||||
Earnings before income taxes
|
5,265
|
3,882
|
8.5
|
7.0
|
||||||||||||
Income taxes
|
1,962
|
2,116
|
3.2
|
3.8
|
||||||||||||
Net earnings for the period
|
$
|
3,303
|
$
|
1,766
|
5.3
|
%
|
3.2
|
%
|
||||||||
Basic and diluted net earnings per share
|
$
|
0.06
|
$
|
0.03
|
||||||||||||
Other selected information:
|
||||||||||||||||
Gross margin before depreciation and amortization (2)
|
$
|
38,972
|
$
|
35,095
|
63.1
|
%
|
63.5
|
%
|
||||||||
Research and development:
|
||||||||||||||||
Gross research and development
|
$
|
12,640
|
$
|
11,279
|
20.5
|
%
|
20.4
|
%
|
||||||||
Net research and development
|
$
|
11,314
|
$
|
9,933
|
18.3
|
%
|
18.0
|
%
|
||||||||
Adjusted EBITDA (2)
|
$
|
6,321
|
$
|
5,286
|
10.2
|
%
|
9.6
|
%
|
(1)
|
The cost of sales is exclusive of depreciation and amortization, shown separately.
|
(2)
|
Refer to page 29 for non-IFRS measures.
|
Three months ended
November 30,
|
||||||||
2016
|
2015
|
|||||||
Physical-layer product line
|
$
|
42,016
|
$
|
37,477
|
||||
Protocol-layer product line
|
20,009
|
18,629
|
||||||
62,025
|
56,106
|
|||||||
Foreign exchange losses on forward exchange contracts
|
(240
|
)
|
(874
|
)
|
||||
Total sales
|
$
|
61,785
|
$
|
55,232
|
Three months ended
November 30,
|
||||||||
2016
|
2015
|
|||||||
Physical-layer product line
|
$
|
44,090
|
$
|
38,878
|
||||
Protocol-layer product line
|
22,009
|
20,469
|
||||||
66,099
|
59,347
|
|||||||
Foreign exchange losses on forward exchange contracts
|
(240
|
)
|
(874
|
)
|
||||
Total bookings
|
$
|
65,859
|
$
|
58,473
|
Three months ended
November 30,
|
||||||||
2016
|
2015
|
|||||||
Americas
|
56
|
%
|
56
|
%
|
||||
EMEA
|
23
|
26
|
||||||
APAC
|
21
|
18
|
||||||
Total bookings
|
100
|
%
|
100
|
%
|
Expiry dates
|
Contractual
amounts
|
Weighted average
contractual
forward rates
|
||||||
December 2016 to August 2017
|
$
|
17,900,000
|
1.2995
|
|||||
September 2017 to August 2018
|
12,700,000
|
1.3376
|
||||||
September 2018 to December 2018
|
2,500,000
|
1.3585
|
||||||
Total
|
$
|
33,100,000
|
1.3185
|
Expiry dates
|
Contractual
amounts
|
Weighted average
contractual
forward rates
|
||||||
December 2016 to August 2017
|
$
|
3,000,000
|
71.06
|
|||||
September 2017 to January 2018
|
2,000,000
|
70.76
|
||||||
$
|
5,000,000
|
70.94
|
Three months ended November 30,
|
||||||||
2016
|
2015
|
|||||||
IFRS net earnings for the period
|
$
|
3,303
|
$
|
1,766
|
||||
Add (deduct):
|
||||||||
Depreciation of property, plant and equipment
|
903
|
975
|
||||||
Amortization of intangible assets
|
427
|
300
|
||||||
Interest (income) expense
|
(20
|
)
|
63
|
|||||
Income taxes
|
1,962
|
2,116
|
||||||
Stock-based compensation costs
|
258
|
376
|
||||||
Foreign exchange gain
|
(512
|
)
|
(310
|
)
|
||||
Adjusted EBITDA for the period
|
$
|
6,321
|
$
|
5,286
|
||||
Adjusted EBITDA in percentage of sales
|
10.2
|
%
|
9.6
|
%
|
Quarters ended
|
||||||||||||||||
November 30,
2016
|
August 31,
2016
|
May 31,
2016
|
February 29,
2016
|
|||||||||||||
Sales
|
$
|
61,785
|
$
|
62,858
|
$
|
60,896
|
$
|
53,597
|
||||||||
Cost of sales (1)
|
$
|
22,813
|
$
|
24,145
|
$
|
23,880
|
$
|
18,904
|
||||||||
Net earnings
|
$
|
3,303
|
$
|
2,252
|
$
|
919
|
$
|
3,963
|
||||||||
Basic and diluted net earnings per share
|
$
|
0.06
|
$
|
0.04
|
$
|
0.02
|
$
|
0.07
|
Quarters ended
|
||||||||||||||||
November 30,
2015
|
August 31,
2015
|
May 31,
2015
|
February 28,
2015
|
|||||||||||||
Sales
|
$
|
55,232
|
$
|
56,594
|
$
|
57,781
|
$
|
50,990
|
||||||||
Cost of sales (1)
|
$
|
20,137
|
$
|
21,975
|
$
|
22,281
|
$
|
19,546
|
||||||||
Net earnings
|
$
|
1,766
|
$
|
1,882
|
$
|
563
|
$
|
931
|
||||||||
Basic and diluted net earnings per share
|
$
|
0.03
|
$
|
0.03
|
$
|
0.01
|
$
|
0.02
|
(1)
|
The cost of sales is exclusive of depreciation and amortization.
|
1. |
Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of EXFO Inc. (the "issuer") for the interim period ended November 30, 2016.
|
2. |
No misrepresentation: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
|
3. |
Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
|
4. |
Responsibility: The issuer's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in Regulation 52-109 respecting Certification of Disclosure in Issuer's Annual and Interim Filings (c. V-1.1, r. 27), for the issuer.
|
5. |
Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer and I have, as at the end of the period covered by the interim filings
|
(a) |
designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
|
(i) |
material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
|
(ii) |
information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
|
(b) |
designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.
|
5.1 |
Control framework: The control framework the issuer's other certifying officer and I used to design the issuer's ICFR is the Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
|
5.2 |
N/A
|
5.3 |
N/A
|
6. |
Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on September 1, 2016 and ended on November 30, 2016 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.
|
1. |
Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of EXFO Inc. (the "issuer") for the interim period ended November 30, 2016.
|
2. |
No misrepresentation: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
|
3. |
Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
|
4. |
Responsibility: The issuer's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in Regulation 52-109 respecting Certification of Disclosure in Issuer's Annual and Interim Filings (c. V-1.1, r. 27), for the issuer.
|
5. |
Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer and I have, as at the end of the period covered by the interim filings
|
(a) |
designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
|
(i) |
material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
|
(ii) |
information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
|
(b) |
designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.
|
5.1 |
Control framework: The control framework the issuer's other certifying officer and I used to design the issuer's ICFR is the Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
|
5.2 |
N/A
|
5.3 |
N/A
|
6. |
Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on September 1, 2016 and ended on November 30, 2016 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.
|